Epigenetics-targeted drugs: current paradigms and future challenges
Open accessThe DOI matches its Crossref record; 1,077 of the 1,077 references it cites were found in a registry or an index.
Abstract
Epigenetics governs a chromatin state regulatory system through five key mechanisms: DNA modification, histone modification, RNA modification, chromatin remodeling, and non-coding RNA regulation. These mechanisms and their associated enzymes convey genetic information independently of DNA base sequences, playing essential roles in organismal development and homeostasis. Conversely, disruptions in epigenetic landscapes critically influence the pathogenesis of various human diseases. This understanding has laid a robust theoretical groundwork for developing drugs that target epigenetics-modifying enzymes in pathological conditions. Over the past two decades, a growing array of small molecule drugs targeting epigenetic enzymes such as DNA methyltransferase, histone deacetylase, isocitrate dehydrogenase, and enhancer of zeste homolog 2, have been thoroughly investigated and implemented as therapeutic options, particularly in oncology. Additionally, numerous epigenetics-targeted drugs are undergoing clinical trials, offering promising prospects for clinical benefits. This review delineates the roles of epigenetics in physiological and pathological contexts and underscores pioneering studies on the discovery and clinical implementation of epigenetics-targeted drugs. These include inhibitors, agonists, degraders, and multitarget agents, aiming to identify practical challenges and promising avenues for future research. Ultimately, this review aims to deepen the understanding of epigenetics-oriented therapeutic strategies and their further application in clinical settings.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 401–600 of 1,077
Nicholls, S. J., Puri, R., Wolski, K., Ballantyne, C. M., Barter, P. J., Brewer, H. B., Kastelein, J. J. P., Hu, B., Uno, K., Kataoka, Y., et al. (2016) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-015-0146-z · Cited by 107
A phase 2 study of mocetinostat, a histone deacetylase inhibitor, in relapsed or refractory lymphoma
Batlevi, C. L., Crump, M., Andreadis, C., Rizzieri, D., Assouline, S. E., Fox, S., van der Jagt, R. H. C., Copeland, A., Potvin, D., Chao, R., et al. (2017) · British Journal of Haematology · doi:10.1111/bjh.14698 · Cited by 107
miR-155 as a novel clinical target for hematological malignancies
Witten, L., & Slack, F. J. (2019) · Carcinogenesis · doi:10.1093/carcin/bgz183 · Cited by 107
The concurrence of DNA methylation and demethylation is associated with transcription regulation
Shi, J., Xu, J., Chen, Y. E., Li, J. S., Cui, Y., Shen, L., Li, J. J., & Li, W. (2021) · Nature Communications · doi:10.1038/s41467-021-25521-7 · Cited by 107
Epigenomic analysis of Parkinson’s disease neurons identifies Tet2 loss as neuroprotective
Marshall, L. L., Killinger, B. A., Ensink, E., Li, P., Li, K. X., Cui, W., Lubben, N., Weiland, M. J., Wang, X., Gordevičius, J., et al. (2020) · Nature Neuroscience · doi:10.1038/s41593-020-0690-y · Cited by 105
Zhang, Q., Xiong, L., Wei, T., Liu, Q., Yan, L., Chen, J., Dai, L., Shi, L., Zhang, W., Yang, J., et al. (2023) · Oncogene · doi:10.1038/s41388-023-02665-y · Cited by 105
Garcia‐Manero, G., Montalban‐Bravo, G., Berdeja, J. G., Abaza, Y., Jabbour, E., Essell, J., Lyons, R. M., Ravandi, F., Maris, M., Heller, B., et al. (2017) · Cancer · doi:10.1002/cncr.30533 · Cited by 104
Reversible Lysine Specific Demethylase 1 (LSD1) Inhibitors: A Promising Wrench to Impair LSD1
Dai, X., Liu, Y., Xue, L.-P., Xiong, X.-P., Zhou, Y., Zheng, Y., & Liu, H. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c02176 · Cited by 104
Yan, F., Li, J., Milosevic, J., Petroni, R., Liu, S., Shi, Z., Yuan, S., Reynaga, J. M., Qi, Y., Rico, J., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1459 · Cited by 104
Self-citationAggarwal, R. R., Thomas, S., Pawłowska, N., Bartelink, I. H., Grabowsky, J. A., Jahan, T. M., Cripps, A., Harb, A., Leng, J. X., Reinert, A., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.5350 · Cited by 103
Venugopal, S., Takahashi, K., Daver, N. G., Maiti, A., Borthakur, G. M., Loghavi, S., Short, N. J., Ohanian, M. N., Masárová, L., Issa, G. C., et al. (2022) · Blood Cancer Journal · doi:10.1038/s41408-021-00604-2 · Cited by 103
Davis, A. J., Gelmon, K. A., Siu, L. L., Moore, M. J., Britten, C. D., Mistry, N., Klamut, H. J., D’Aloisio, S., MacLean, M., Wainman, N., et al. (2003) · Investigational New Drugs · doi:10.1023/a:1022976528441 · Cited by 102
Galloway, T. J., Wirth, L. J., Colevas, A. D., Gilbert, J., Bauman, J. E., Saba, N. F., Raben, D., Mehra, R., Ma, A. W., Atoyan, R., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2820 · Cited by 102
Prébet, T., Sun, Z., Ketterling, R. P., Zeidan, A. M., Greenberg, P. L., Herman, J. G., Juckett, M., Smith, M. R., Malick, L., Paietta, E. M., et al. (2015) · British Journal of Haematology · doi:10.1111/bjh.13832 · Cited by 102
Ameratunga, M., Braña, I., Bono, P., Postel-Vinay, S. C., Plummer, R., Aspegrén, J., Korjamo, T., Snapir, A., & Bono, J. S. D. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-01077-z · Cited by 102
Targeted attenuation of elevated histone marks at SNCA alleviates α‐synuclein in Parkinson's disease
Guhathakurta, S., Kim, J.-I., Adams, L., Basu, S., Song, M. K., Adler, E. R., Je, G., Fiadeiro, M. B., & Kim, Y. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202012188 · Cited by 102
Yu, H., Chen, M., Hu, Y., Ou, S., Xiu, Y., Liang, S., Li, N., Yang, M., Kong, X., Sun, C., et al. (2022) · Cell stem cell · doi:10.1016/j.stem.2022.06.006 · Cited by 102
Epigenetic clocks, aging, and cancer
Johnstone, S. E., Gladyshev, V. N., Aryee, M. J., & Bernstein, B. (2022) · Science · doi:10.1126/science.abn4009 · Cited by 102
Richards, D. A., Boehm, K. A., Waterhouse, D. M., Wagener, D. J., Krishnamurthi, S. S., Rosemurgy, A., Grove, W., Macdonald, K., Gulyas, S., Clark, M., et al. (2006) · Annals of Oncology · doi:10.1093/annonc/mdl081 · Cited by 101
Park, H., Shin, J., Kim, Y.-K., Saito, T., Saido, T. C., & Kim, J. (2022) · Translational Neurodegeneration · doi:10.1186/s40035-022-00314-0 · Cited by 100
Decoding p53 tumor suppression: a crosstalk between genomic stability and epigenetic control?
Janic, A., Abad, E., & Amelio, I. (2024) · Cell Death and Differentiation · doi:10.1038/s41418-024-01259-9 · Cited by 100
Shenoy, N. K., Bhagat, T. D., Cheville, J. C., Lohse, C. M., Bhattacharyya, S., Tischer, A., Machha, V. R., Gordon-Mitchell, S., Choudhary, G. S., Wong, L.-F., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci98747 · Cited by 99
Garcia‐Manero, G., Roboz, G. J., Walsh, K. J., Kantarjian, H. M., Ritchie, E. K., Kropf, P. L., O'Connell, C. L., Tibes, R., Lunin, S. D., Rosenblat, T. L., et al. (2019) · The Lancet Haematology · doi:10.1016/s2352-3026(19)30029-8 · Cited by 99
Gillberg, L., Ørskov, A. D., Nasif, A., Ohtani, H., Madaj, Z., Hansen, J. W., Rapin, N., Mogensen, J. B., Liu, M., Dufva, I. H., et al. (2019) · Clinical Epigenetics · doi:10.1186/s13148-019-0739-5 · Cited by 99
Liao, J., Wei, Y., Liang, J., Wen, J., Chen, X., Zhang, B., & Chu, L. (2022) · Cell Death Discovery · doi:10.1038/s41420-022-00947-0 · Cited by 99
A phase 2 study of intravenous panobinostat in patients with castration-resistant prostate cancer
Rathkopf, D. E., Picus, J., Hussain, A., Ellard, S. L., Chi, K. N., Nydam, T., Allen-Freda, E., Mishra, K., Porro, M. G., Scher, H. I., et al. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2224-8 · Cited by 98
Adkins, N. L., & Georgel, P. T. (2011) · Biochemistry and Cell Biology · doi:10.1139/o10-112 · Cited by 98
Thomas, A., Rajan, A., Szabo, E. M., Tomita, Y., Carter, C. A., Scepura, B., López-Chávez, A., Lee, M.-J., Redon, C. E., Frosch, A., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0968 · Cited by 98
Пили, Р., Quinn, D. I., Hammers, H. J., Monk, P., George, S., Dorff, T. B., Olencki, T. E., Shen, L., Orillion, A. R., Lamonica, D. M., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1178 · Cited by 98
Readers of DNA methylation, the MBD family as potential therapeutic targets
Ginder, G. D., & Williams, D. C. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.11.002 · Cited by 98
Broussy, S., Laaroussi, H., & Vidal, M. (2020) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2020.1758691 · Cited by 98
Soldi, R., Ghosh, T., Weston, A., Thode, T. G., Drenner, K., Lewis, R., Kaadige, M. R., Srivastava, S., Ampanattu, S. D., del Villar, R. R., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0235705 · Cited by 98
BET proteins: Biological functions and therapeutic interventions
Guo, J., Zheng, Q., & Peng, Y. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108354 · Cited by 98
Nicholls, S. J., Gordon, A., Johannson, J., Ballantyne, C. M., Barter, P. J., Brewer, H. B., Kastelein, J. J. P., Wong, N. C. W., Borgman, M., & Nissen, S. E. (2012) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-012-6373-5 · Cited by 97
Ribrag, V., Kim, W. S., Bouabdallah, R., Lim, S. T., Coiffier, B., Illes, A., Lemieux, B., Dyer, M. J. S., Offner, F., Felloussi, Z., et al. (2017) · Haematologica · doi:10.3324/haematol.2016.154377 · Cited by 97
Bauer, T. M., Besse, B., Martínez‐Martí, A., Trigo, J. M., Moreno, V., Garrido, P., Ferron‐Brady, G., Wu, Y., Park, J., Collingwood, T. S., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.06.021 · Cited by 97
Jensen-Pergakes, K., Tatlock, J., Maegley, K. A., McAlpine, I. J., McTigue, M., Xie, T., Dillon, C. P., Wang, Y., Yamazaki, S., Spiegel, N., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0620 · Cited by 97
Inhibition of the m6A reader IGF2BP2 as a strategy against T-cell acute lymphoblastic leukemia
Feng, P., Chen, D., Wang, X., Li, Y., Li, Z., Li, B., Zhang, Y., Li, W., Zhang, J., Ye, J., et al. (2022) · Leukemia · doi:10.1038/s41375-022-01651-9 · Cited by 97
Zhang, Y., Song, H., Li, M., & Lu, P. (2024) · Clinical and Translational Medicine · doi:10.1002/ctm2.1614 · Cited by 97
Evens, A. M., Balasubramanian, S., Vose, J. M., Harb, W., Gordon, L. I., Langdon, R., Sprague, J., Sirisawad, M., Mani, C., Yue, J., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0624 · Cited by 96
D-2-Hydroxyglutarate in Glioma Biology
Chou, F.-J., Liu, Y., Lang, F., & Yang, C. (2021) · Cells · doi:10.3390/cells10092345 · Cited by 96
Cao, K., Du, Y., Bao, X., Han, M., Su, R. J., Pang, J., Liu, S., Shi, Z., Yan, F., & Feng, S. (2022) · Small · doi:10.1002/smll.202106558 · Cited by 96
Self-citationMascarenhas, J. O., Kremyanskaya, M., Patriarca, A., Palandri, F., Devos, T., Passamonti, F., Rampal, R. K., Mead, A. J., Hobbs, G. S., Scandura, J. M., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.01972 · Cited by 96
Phase 1 study of GSK3368715, a type I PRMT inhibitor, in patients with advanced solid tumors
El-Khoueiry, A. B., Clarke, J., Neff, T., Crossman, T., Ratia, N., Rathi, C. D., Noto, P. B., Tarkar, A., Garrido‐Laguna, I., Calvo, E., et al. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02276-0 · Cited by 96
Global identification of SWI/SNF targets reveals compensation by EP400
Martin, B. J. E., Ablondi, E. F., Goglia, C., Mimoso, C. A., Espinel-Cabrera, P. R., & Adelman, K. (2023) · Cell · doi:10.1016/j.cell.2023.10.006 · Cited by 96
Discovery of METTL3 Small Molecule Inhibitors by Virtual Screening of Natural Products
Du, Y., Yuan, Y., Xu, L., Zhao, F., Wang, W., Xu, Y., & Tian, X. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.878135 · Cited by 95
Sirtuin Inhibition: Strategies, Inhibitors, and Therapeutic Potential
Jiang, Y., Liu, J., Chen, D., Yan, L., & Zheng, W. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.01.009 · Cited by 94
Self-citationA phase II, multicentre trial of decitabine in higher-risk chronic myelomonocytic leukemia
Santini, V., Allione, B., Zini, G., Gioia, D. M., Lunghi, M., Poloni, A., Cilloni, D., Sanna, A., Masiera, E., Ceccarelli, M., et al. (2017) · Leukemia · doi:10.1038/leu.2017.186 · Cited by 94
α-ketoglutarate dehydrogenase inhibition counteracts breast cancer-associated lung metastasis
Atlante, S., Visintin, A., Marini, E., Savoia, M., Dianzani, C., Giorgis, M., Sürün, D., Maione, F., Schnütgen, F., Farsetti, A., et al. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0802-8 · Cited by 94
Zhang, Q., Xiao, X., Zheng, J., Li, M., Yu, M., Ping, F., Wang, T., & Wang, X. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00871 · Cited by 94
Self-citationTherapeutic potential of tucidinostat, a subtype-selective HDAC inhibitor, in cancer treatment
Sun, Y., Hong, J. H., Ning, Z., Pan, D., Fu, X., Lu, X., & Tan, J. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.932914 · Cited by 94
Suzuki, T., Ozasa, H., Itoh, Y., Zhan, P., Sawada, H., Mino, K., Walport, L. J., Ohkubo, R., Kawamura, A., Yonezawa, M., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400624b · Cited by 93
Desai, M. A., Webb, H. D., Sinanan, L. M., Scarsdale, J. N., Walavalkar, N. M., Ginder, G. D., & Williams, D. C. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv168 · Cited by 93
Discovery of an MLLT1/3 YEATS Domain Chemical Probe
Moustakim, M., Christott, T., Monteiro, O., Bennett, J. M., Giroud, C., Ward, J., Rogers, C. M., Smith, P., Panagakou, I., Saez, L. D., et al. (2018) · Angewandte Chemie International Edition · doi:10.1002/anie.201810617 · Cited by 93
Oza, A. M., Matulonis, U. A., Secord, A. A., Nemunaitis, J. J., Roman, L. D., Blagden, S. P., Banerjee, S. N., McGuire, W. P., Ghamande, S. A., Birrer, M. J., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1638 · Cited by 93
Morrison-Smith, C. D., Knox, T. M., Filic, I., Soroko, K. M., Eschle, B. K., Wilkens, M. K., Gokhale, P. C., Giles, F. J., Griffin, A. M., Brown, B., et al. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0087 · Cited by 93
Context-specific functions of chromatin remodellers in development and disease
Gourisankar, S. P., Krokhotin, A., Wenderski, W., & Crabtree, G. R. (2023) · Nature Reviews Genetics · doi:10.1038/s41576-023-00666-x · Cited by 93
Zeidan, A. M., Ando, K., Beyne‐Rauzy, O., Turgut, M., Wang, M., Cairoli, R., Hou, H., Kwong, Y., Arnán, M., Meers, S., et al. (2023) · The Lancet Haematology · doi:10.1016/s2352-3026(23)00333-2 · Cited by 93
Brueckner, B., Rius, M., Markelova, M. R., Fichtner, I., Hals, P., Sandvold, M. L., & Lyko, F. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-1202 · Cited by 92
The novel BET‐CBP/p300 dual inhibitor NEO2734 is active in SPOP mutant and wild‐type prostate cancer
Yan, Y., Ma, J., Wang, D., Lin, D., Pang, X., Wang, S., Zhao, Y., Shi, L., Xue, H., Pan, Y., et al. (2019) · EMBO Molecular Medicine · doi:10.15252/emmm.201910659 · Cited by 92
Interpreting non-coding disease-associated human variants using single-cell epigenomics
Gaulton, K. J., Preißl, S., & Ren, B. (2023) · Nature Reviews Genetics · doi:10.1038/s41576-023-00598-6 · Cited by 92
Cottrell, K. M., Briggs, K. J., Whittington, D. A., Jahić, H., Ali, J. A., Davis, C. B., Gong, S., Gotur, D., Gu, L., McCarren, P. R., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00133 · Cited by 92
Xue, Y., Morris, J. L., Yang, K., Fu, Z., Zhu, X., Johnson, F. D., Meehan, B., Witkowski, L., Yasmeen, A., Golenár, T., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25260-9 · Cited by 91
de la Fuente, M. I., Colman, H., Rosenthal, M. A., Tine, B. A. V., Levacic, D., Walbert, T., Gan, H. K., Vieito, M., Milhem, M. M., Lipford, K., et al. (2022) · Neuro-Oncology · doi:10.1093/neuonc/noac139 · Cited by 91
Micaelli, M., Vedove, A. D., Cerofolini, L., Vigna, J., Sighel, D., Zaccara, S., Bonomo, I., Poulentzas, G., Rosatti, E. F., Cazzanelli, G., et al. (2022) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.2c00008 · Cited by 91
Epigenetic regulation of B cells and its role in autoimmune pathogenesis
Xiao, F., Rui, K., Shi, X., Wu, H., Cai, X., Lui, K. O., Lu, Q., Ballestar, E., Tian, J., Zou, H., et al. (2022) · Cellular and Molecular Immunology · doi:10.1038/s41423-022-00933-7 · Cited by 91
IFN-γ signature enables selection of neoadjuvant treatment in patients with stage III melanoma
Reijers, I. L. M., Rao, D., Versluis, J. M., Menzies, A. M., Dimitriadis, P., Wouters, M. W. J. M., Spillane, A. J., Klop, W. M. C., Broeks, A., Bosch, L. J. W., et al. (2023) · The Journal of Experimental Medicine · doi:10.1084/jem.20221952 · Cited by 91
Peng, X., Hu, Z., Zeng, L., Zhang, M., Xu, C., Lu, B., Tao, C., Chen, W., Hou, W., Cheng, K., et al. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.09.003 · Cited by 91
Bo, S., Togliatto, G., Gambino, R., Ponzo, V., Lombardo, G., Rosato, R., Cassader, M., & Brizzi, M. F. (2018) · Acta Diabetologica · doi:10.1007/s00592-017-1097-4 · Cited by 89
Li, X., & Song, Y. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01057-7 · Cited by 89
Ren, B., Yang, J., Wang, C., Yang, G., Wang, H., Chen, Y., Xu, R., Fan, X., You, L., Zhang, T., et al. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01131-0 · Cited by 88
Epigenetic priming enhances antitumor immunity in platinum-resistant ovarian cancer
Chen, S., Xie, P., Cowan, M. L., Huang, H., Cárdenas, H., Keathley, R., Tanner, E. J., Fleming, G. F., Moroney, J. W., Pant, A., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci158800 · Cited by 88
Dynamics of histone acetylation during human early embryogenesis
Wu, K., Fan, D., Zhao, H., Liu, Z., Hou, Z., Tao, W., Yu, G., Yuan, S., Zhu, X., Kang, M., et al. (2023) · Cell Discovery · doi:10.1038/s41421-022-00514-y · Cited by 88
Promising role of protein arginine methyltransferases in overcoming anti-cancer drug resistance
Zhu, Y., Xia, T., Chen, D.-Q., Xiong, X., Shi, L., Zuo, Y., Xiao, H., & Liu, L. (2023) · Drug Resistance Updates · doi:10.1016/j.drup.2023.101016 · Cited by 88
The Histone Methyltransferase DOT1L Promotes Neuroblastoma by Regulating Gene Transcription
Wong, M., Tee, A. E., Milazzo, G., Bell, J. L., Poulos, R. C., Atmadibrata, B., Sun, Y., Jing, D., Ho, N., Ling, D., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-1663 · Cited by 87
Liu, R., Gao, J., Yang, Y., Qiu, R., Zheng, Y., Huang, W., Zeng, Y., Hou, Y., Wang, S., Leng, S., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky461 · Cited by 87
Identification of Natural Compound Radicicol as a Potent FTO Inhibitor
Wang, R., Han, Z., Liu, B., Zhou, B., Wang, N., Jiang, Q., Qiao, Y., Song, C., Chai, J., & Chang, J. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00522 · Cited by 87
the BETonMACE Investigators, Nicholls, S. J., Schwartz, G. G., Buhr, K. A., Ginsberg, H. N., Johansson, J. O., Kalantar‐Zadeh, K., Kulikowski, E., Toth, P. P., Wong, N. C. W., et al. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01199-x · Cited by 87
Inhibition of METTL3 Alleviates NLRP3 Inflammasome Activation via Increasing Ubiquitination of NEK7
Zhou, X., Yang, X., Huang, S., Lin, G., Lei, K., Wang, Q., Lin, W., Li, H., Qi, X., Seriwatanachai, D., et al. (2024) · Advanced Science · doi:10.1002/advs.202308786 · Cited by 87
Structural insights into selective histone H3 recognition by the human Polybromo bromodomain 2
Charlop–Powers, Z., Zeng, L., Zhang, Q., & Zhou, M. (2010) · Cell Research · doi:10.1038/cr.2010.43 · Cited by 86
Developing potent LC3-targeting AUTAC tools for protein degradation with selective autophagy
Pei, J., Pan, X., Wang, A., Shuai, W., Bu, F., Tang, P., Zhang, S., Zhang, Y., Wang, G., & Ouyang, L. (2021) · Chemical Communications · doi:10.1039/d1cc04661f · Cited by 86
Shimizu, T., LoRusso, P. M., Papadopoulos, K. P., Patnaik, A., Beeram, M., Smith, L. S., Rasco, D. W., Mays, T. A., Chambers, G., Ma, A., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0570 · Cited by 85
Histone benzoylation serves as an epigenetic mark for DPF and YEATS family proteins
Ren, X., Zhou, Y., Xue, Z., Hao, N., Li, Y., Guo, X., Wang, D., Shi, X., & Li, H. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa1130 · Cited by 85
DNA methylation and type 2 diabetes: a systematic review
Nadiger, N., Veed, J. K., Nataraj, P. C., & Mukhopadhyay, A. (2024) · Clinical Epigenetics · doi:10.1186/s13148-024-01670-6 · Cited by 85
Candelaria, M., Herrera, A., Labardini, J., González‐Fierro, A., Trejo‐Becerril, C., Taja‐Chayeb, L., Pérez‐Cárdenas, E., la Cruz-Hernández, E. N. D., Arias-Bofill, D., Vidal, S., et al. (2010) · Annals of Hematology · doi:10.1007/s00277-010-1090-2 · Cited by 84
Epigenetic regulation of tumor immunity
Pang, L., Zhou, F., Liu, Y., Ali, H. A., Khan, F., Heimberger, A. B., & Chen, P. (2024) · Journal of Clinical Investigation · doi:10.1172/jci178540 · Cited by 84
Human DNMT1 transition state structure
Du, Q., Wang, Z., & Schramm, V. L. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1522491113 · Cited by 83
Complex chromosomal rearrangements by single catastrophic pathogenesis in NUT midline carcinoma
Lee, J. J.-K., Louzada, S., An, Y., Kim, S. Y., Kim, S., Youk, J., Park, S., Koo, S. H., Keam, B., Jeon, Y. K., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw686 · Cited by 83
Gruell, H., Gunst, J. D., Cohen, Y. Z., Pahus, M. H., Malin, J. J., Platten, M., Millard, K. G., Tolstrup, M., Jones, R. B., Conce Alberto, W. D., et al. (2022) · The Lancet Microbe · doi:10.1016/s2666-5247(21)00239-1 · Cited by 82
Monje, M., Cooney, T. M., Glod, J. W., Huang, J., Peer, C. J., Faury, D., Baxter, P. A., Kramer, K., Lenzen, A. C., Robison, N. J., et al. (2023) · Neuro-Oncology · doi:10.1093/neuonc/noad141 · Cited by 82
DNA methyltransferases in hematological malignancies
Hoang, N.-M., & Rui, L. (2020) · Journal of genetics and genomics/Journal of Genetics and Genomics · doi:10.1016/j.jgg.2020.04.006 · Cited by 81
Class I and II histone deacetylase inhibition by ITF2357 reduces SLE pathogenesis in vivo
Regna, N. L., Chafin, C. B., Hammond, S. E., Puthiyaveetil, A. G., Caudell, D. L., & Reilly, C. M. (2014) · Clinical Immunology · doi:10.1016/j.clim.2014.01.002 · Cited by 80
Zinc-dependent Deacetylase (HDAC) Inhibitors with Different Zinc Binding Groups
Li, Y., Wang, F., Chen, X., Wang, J., Zhao, Y., Li, Y., & He, B. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666190122144949 · Cited by 80
Methylome Dynamics of Bovine Gametes and in vivo Early Embryos
Duan, J. E., Jiang, Z., Alqahtani, F. A., Măndoiu, I., Dong, H., Zheng, X., Marjani, S. L., Chen, J., & Tian, X. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00512 · Cited by 80
Small molecule inhibitor of Igf2bp1 represses Kras and a pro-oncogenic phenotype in cancer cells
Wallis, N., Oberman, F., Shurrush, K. A., Germain, N., Greenwald, G., Gershon, T., Pearl, T., Abis, G., Singh, V., Singh, A., et al. (2021) · RNA Biology · doi:10.1080/15476286.2021.2010983 · Cited by 80
Genetics and epigenetics of autoimmune thyroid diseases: Translational implications
Lee, H. J., Stefan–Lifshitz, M., Li, C. W., & Tomer, Y. (2022) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2022.101661 · Cited by 80
Sutherell, C. L., Tallant, C., Monteiro, O., Yapp, C., Fuchs, J. E., Fedorov, O., Siejka, P., Müller, S., Knapp, S., Brenton, J. D., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01997 · Cited by 79
Sinatra, L., Yang, J. C., Schliehe‐Diecks, J., Dienstbier, N., Vogt, M., Gebing, P., Bachmann, L. M., Sönnichsen, M., Lenz, T., Stühler, K., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01659 · Cited by 79
Garcia‐Manero, G., Sekeres, M. A., Egyed, M., Breccia, M., Graux, C., Cavenagh, J. D., Salman, H., Illés, Á., Fenaux, P., DeAngelo, D. J., et al. (2017) · Leukemia · doi:10.1038/leu.2017.159 · Cited by 78
Garcia-Manero, G., Abaza, Y., Takahashi, K., Medeiros, B. C., Arellano, M., Khaled, S. K., Patnaik, M., Odenike, O., Sayar, H., Tummala, M., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2018027409 · Cited by 78
Therapy with the histone deacetylase inhibitor pracinostat for patients with myelofibrosis
Quintás‐Cardama, A., Kantarjian, H. M., Estrov, Z. E., Borthakur, G. M., Cortes, J. E., & Verstovšek, S. (2012) · Leukemia Research · doi:10.1016/j.leukres.2012.03.003 · Cited by 77
Yang, G., Ko, C.-N., Zhong, H., Leung, C., & Ma, D. (2019) · Cancers · doi:10.3390/cancers11010092 · Cited by 77
Kawabe, Y., Mori, J., Morimoto, H., Yamaguchi, M., Miyagaki, S., Ota, T., Tsuma, Y., Fukuhara, S., Nakajima, H., Oudit, G. Y., et al. (2019) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00311.2019 · Cited by 77
Metformin exhibits antiproliferation activity in breast cancer via miR-483-3p/METTL3/m6A/p21 pathway
Cheng, L., Zhang, X., Huang, Y., Zhu, Y., Xu, L.-Y., Li, Z., Dai, X., Shi, L., Zhou, S., Wei, J., et al. (2021) · Oncogenesis · doi:10.1038/s41389-020-00290-y · Cited by 77
Rational Design and Optimization of m6A-RNA Demethylase FTO Inhibitors as Anticancer Agents
Huff, S. E., Kummetha, I. R., Zhang, L., Wang, L., Bray, W., Yin, J., Kelley, V. M., Wang, Y., & Rana, T. M. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c02075 · Cited by 77
Pharmacological targeting of the cancer epigenome
Mabe, N. W., Perry, J. A., Malone, C. F., & Stegmaier, K. (2024) · Nature Cancer · doi:10.1038/s43018-024-00777-2 · Cited by 77
Zhang, Y., Yang, H., Guo, X., Rong, N., Song, Y., Xu, Y., Lan, W., Zhang, X., Liu, M., Xu, Y., et al. (2014) · Protein & Cell · doi:10.1007/s13238-014-0078-4 · Cited by 76
Histone deacetylase (HDAC) 9: versatile biological functions and emerging roles in human cancer
Yang, C., Croteau, S., & Hardy, P. (2021) · Cellular Oncology · doi:10.1007/s13402-021-00626-9 · Cited by 76
Emerging Roles of RNA Methylation in Development
Wang, M., Gao, C., & Yang, Y. (2023) · Accounts of Chemical Research · doi:10.1021/acs.accounts.3c00448 · Cited by 76
Undevia, S. D., Kindler, H. L., Janisch, L. A., Olson, S. C., Schilsky, R. L., Vogelzang, N. J., Kimmel, K. A., Macek, T. A., & Ratain, M. J. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh438 · Cited by 75
Wick, A., Bähr, O., Schüler, M., Rohrberg, K. S., Chawla, S. P., Jankú, F., Schiff, D., Heinemann, V., Narita, Y., Lenz, H., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4256 · Cited by 75
Borthakur, G. M., Odenike, O. M., Aldoss, I. T., Rizzieri, D. A., Prébet, T., Chen, C., Popovic, R., Modi, D., Joshi, R. H., Wolff, J. E. A., et al. (2021) · Cancer · doi:10.1002/cncr.33590 · Cited by 75
Advances in the DNA methylation hydroxylase TET1
Liu, W., Wu, G., Xiong, F., & Chen, Y. (2021) · Biomarker Research · doi:10.1186/s40364-021-00331-7 · Cited by 75
Discovery of a potent, selective and cell active inhibitor of m6A demethylase ALKBH5
Fang, Z. Y., Mu, B., Liu, Y., Guo, N., Liang, X., Guo, Y., Xia, A., Zhang, R., Zhang, H., Yao, R., et al. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114446 · Cited by 75
Xu, B., Zhang, Q., Hu, X., Li, Q., Sun, T., Li, W., Ouyang, Q., Wang, J., Tong, Z., Yan, M., et al. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.02.001 · Cited by 75
Li, Z., Feng, Y., Han, H. J., Jiang, X., Chen, W., Ma, X., Yang, M., Yuan, D., Zhang, D., & Shi, J. (2024) · Angewandte Chemie International Edition · doi:10.1002/anie.202402611 · Cited by 75
Adhikari, N., Jha, T., & Ghosh, B. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01676 · Cited by 74
Bates, S. E., Eisch, R. A., Ling, A. L., Rosing, D. R., Turner, M. L. C., Pittaluga, S., Prince, H. M., Kirschbaum, M. H., Allen, S. L., Zain, J. M., et al. (2015) · British Journal of Haematology · doi:10.1111/bjh.13400 · Cited by 74
Urick, A. K., Hawk, L. M. L., Cassel, M. K., Mishra, N. K., Liu, S., Adhikari, N., Zhang, W., dos Santos, C. O., Hall, J. L., & Pomerantz, W. C. K. (2015) · ACS Chemical Biology · doi:10.1021/acschembio.5b00483 · Cited by 74
Self-citationSpallotta, F., Cencioni, C., Atlante, S., Garella, D., Cocco, M., Mori, M., Mastrocola, R., Kuenne, C. T., Günther, S., Nanni, S., et al. (2017) · Circulation Research · doi:10.1161/circresaha.117.311300 · Cited by 74
DNA methyltransferases: emerging targets for the discovery of inhibitors as potent anticancer drugs
Yu, J., Xie, T., Wang, Z., Wang, X., Zeng, S., Kang, Y., & Hou, T. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.08.006 · Cited by 74
Liu, F., Xu, Y., Lu, X., Hamard, P.-J., Karl, D. L., Man, N., Mookhtiar, A. K., Martínez, C., Lossos, I. S., Sun, J., et al. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa065 · Cited by 74
Zhang, Q., Chen, Y., Ni, D., Huang, Z., Wei, J., Li, F., Su, J., Wei, Y., Ning, S., Yang, X., et al. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.06.015 · Cited by 74
TET2 as a tumor suppressor and therapeutic target in T-cell acute lymphoblastic leukemia
Bensberg, M., Rundquist, O., Selimović-Pašić, A., Lagerwall, C., Benson, M., Gustafsson, M., Vogt, H., Lentini, A., & Nestor, C. E. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2110758118 · Cited by 74
Singh, M., Popowicz, G. M., Krajewski, M., & Holak, T. A. (2007) · ChemBioChem · doi:10.1002/cbic.200600562 · Cited by 73
Takahashi, H., Hase, H., Yoshida, T., Tashiro, J., Hirade, Y., Kitae, K., & Tsujikawa, K. (2022) · Chemical Biology & Drug Design · doi:10.1111/cbdd.14051 · Cited by 73
BAF Complex Maintains Glioma Stem Cells in Pediatric H3K27M Glioma
Panditharatna, E., Marques, J. G., Wang, T., Trissal, M. C., Liu, I., Jiang, L., Beck, A., Groves, A. P., Dharia, N. V., Li, D., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1491 · Cited by 73
Self-citationRuan, J., Moskowitz, A. J., Mehta–Shah, N., Sokol, L., Chen, Z., Kotlov, N., Nos, G., Sorokina, M. A., Maksimov, V., Sboner, A., et al. (2023) · Blood · doi:10.1182/blood.2022018254 · Cited by 73
Jespersen, H., Bagge, R. O., Ullenhag, G. J., Carneiro, A., Helgadóttir, H., Ljuslinder, I., Levin, M., All‐Eriksson, C., Andersson, B. A., Stierner, U. K., et al. (2019) · BMC Cancer · doi:10.1186/s12885-019-5623-3 · Cited by 72
Moreno, V., Sepúlveda-Sánchez, J. M., Vieito, M., Hernández‐Guerrero, T., Doger, B., Saavedra, O., Ferrero, O., Sarmiento, R., Arias, M., de Alvaro, J., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.03.294 · Cited by 72
Lee, J., Choi, N., Kim, S., Jin, M. S., Shen, H., & Kim, Y. (2022) · Pharmaceuticals · doi:10.3390/ph15040440 · Cited by 72
Rai, S., Kim, W. S., Ando, K., Choi, I., Izutsu, K., Tsukamoto, N., Yokoyama, M., Tsukasaki, K., Kuroda, J., Ando, J., et al. (2022) · Haematologica · doi:10.3324/haematol.2022.280996 · Cited by 72
MicroRNA-133a regulates DNA methylation in diabetic cardiomyocytes
Chavali, V., Tyagi, S. C., & Mishra, P. K. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.07.105 · Cited by 71
Therapeutic applications of histone deacetylase inhibitors in sarcoma
Tang, F., Choy, E., Tu, C., Hornicek, F. J., & Duan, Z. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.06.006 · Cited by 71
Ferrari, A. C., Alumkal, J. J., Stein, M. N., Taplin, M., Babb, J. S., Barnett, E. S., Gómez-Pinillos, A., Liu, X., Moore, D. F., DiPaola, R. S., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1589 · Cited by 71
Prasanth, M. I., Sivamaruthi, B. S., Cheong, C. S. Y., Verma, K., Tencomnao, T., Brimson, J. M., & Prasansuklab, A. (2024) · Antioxidants · doi:10.3390/antiox13050606 · Cited by 71
Leadem, B. R., Kagiampakis, I., WILSON, C. A., Cheung, T. K., Arnott, D. P., Trojer, P., Classon, M., Easwaran, H., & Baylin, S. B. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-1453 · Cited by 70
Laubach, J. P., Schjesvold, F. H., Mariz, M., Dimopoulos, M. A., Lech‐Marańda, E., Špıčka, I., Hungria, V., Shelekhova, T. V., Abdo, A., Jacobasch, L., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30680-x · Cited by 70
Cousin, S., Blay, J., Braña, I., Bono, J. S. D., Tourneau, C. L., Moreno, V., Trigo, J. M., Hann, C. L., Azad, A., Im, S., et al. (2021) · International Journal of Cancer · doi:10.1002/ijc.33861 · Cited by 70
Recent Advances with KDM4 Inhibitors and Potential Applications
Wu, Q., Young, B. M., Wang, Y., Davidoff, A. M., Ranković, Z., & Yang, J. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00680 · Cited by 70
Low-dose chidamide restores immune tolerance in ITP in mice and humans
Zhao, H., Ma, Y., Li, D.-Q., Sun, T., Li, L.-Z., Li, P., Liu, X., Zhou, H., Hou, Y., Liu, Y., et al. (2018) · Blood · doi:10.1182/blood-2018-05-847624 · Cited by 69
Self-citationModulation of KDM1A with vafidemstat rescues memory deficit and behavioral alterations
Maes, T., Mascaró, C., Rotllant, D., Lufino, M. M., Estiarte, A., Guibourt, N., Cavalcanti, F., Griñán‐Ferré, C., Pallàs, M., Nadal, R. A., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0233468 · Cited by 69
Heissenberger, C., Rollins, J. A., Krammer, T. L., Nagelreiter, F., Stocker, I., Wacheul, L., Shpylovyi, A., Tav, K., Snow, S., Grillari, J., et al. (2020) · eLife · doi:10.7554/elife.56205 · Cited by 69
Pu, J., Liu, T., Wang, X., Sharma, A., Schmidt‐Wolf, I. G. H., Jiang, L., & Hou, J. (2024) · Experimental Hematology and Oncology · doi:10.1186/s40164-024-00507-5 · Cited by 69
Targeted inhibition of STAT/TET1 axis as a therapeutic strategy for acute myeloid leukemia
Jiang, X., Hu, C., Ferchen, K., Nie, J., Cui, X., Chen, C.-H., Cheng, L., Zuo, Z., Seibel, W., He, C., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-02290-w · Cited by 68
The KDM4/JMJD2 histone demethylases are required for hematopoietic stem cell maintenance
Agger, K., Nishimura, K., Miyagi, S., Messling, J., Rasmussen, K. D., & Helin, K. (2019) · Blood · doi:10.1182/blood.2019000855 · Cited by 68
Response to upfront azacitidine in juvenile myelomonocytic leukemia in the AZA-JMML-001 trial
Niemeyer, C. M., Flotho, C., Lipka, D. B., Starý, J., Rössig, C., Baruchel, A., Klingebiel, T., Micalizzi, C., Michel, G., Nysom, K., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020004144 · Cited by 68
Inhibition of Human Sirtuins by in Situ Generation of an Acetylated Lysine−ADP−Ribose Conjugate
Asaba, T., Suzuki, T., Ueda, R., Tsumoto, H., Nakagawa, H., & Miyata, N. (2009) · Journal of the American Chemical Society · doi:10.1021/ja807083y · Cited by 67
Identification of a Fragment-like Small Molecule Ligand for the Methyl-lysine Binding Protein, 53BP1
Perfetti, M. T., Baughman, B. M., Dickson, B. M., Mu, Y., Cui, G., Mäder, P., Dong, A., Norris, J. L., Rothbart, S. B., Strahl, B. D., et al. (2015) · ACS Chemical Biology · doi:10.1021/cb500956g · Cited by 67
Dynamics of Methylated Cytosine Flipping by UHRF1
Kilin, V., Gavvala, K., Barthes, N. P. F., Michel, B. Y., Shin, D., Boudier, C., Mauffret, O., Yashchuk, V. M. N., Mousli, M., Ruff, M., et al. (2017) · Journal of the American Chemical Society · doi:10.1021/jacs.7b00154 · Cited by 67
Selective targeting of TET catalytic domain promotes somatic cell reprogramming
Singh, A. K., Zhao, B., Liu, X., Wang, X., Li, H., Qin, H., Wu, X., Ma, Y., Horne, D. A., & Yu, X. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1910702117 · Cited by 67
Zhang, Y., Li, Q., Zhou, K., Xu, Q., & Zhang, C. (2020) · Analytical Chemistry · doi:10.1021/acs.analchem.0c02828 · Cited by 67
Mozzetta, C., Sartorelli, V., & Puri, P. (2024) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2024.01.007 · Cited by 67
Razak, A. R. A., Hotte, S. J., Siu, L. L., Chen, E. X., Hirte, H. W., Powers, J., Walsh, W., Stayner, L.-A., Laughlin, A., Novotny-Diermayr, V, et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.13 · Cited by 66
Colyn, L., Bárcena‐Varela, M., Álvarez‐Sola, G., Latasa, M. U., Uriarte, I., Santamaría, E., Herranz, J. M., Santos‐Laso, Á., Arechederra, M., de Gauna, M. R., et al. (2020) · Hepatology · doi:10.1002/hep.31642 · Cited by 66
Papadatos-Pastos, D., Yuan, W., Pal, A., Crespo, M., Ferreira, A., Gürel, B., Prout, T., Ameratunga, M., Chénard-Poirier, M., Curcean, A., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004495 · Cited by 66
Torres, E. T. R., Ho, W. J., Danilova, L., Tandurella, J. A., Leatherman, J. M., Rafie, C. I., Wang, C., Brufsky, A., LoRusso, P. M., Chung, V. M., et al. (2024) · Nature Cancer · doi:10.1038/s43018-024-00729-w · Cited by 66
Feng, L., Wang, G., Chen, Y., He, G., Liu, B., Liu, J., Chiang, C., & Ouyang, L. (2022) · Medicinal Research Reviews · doi:10.1002/med.21859 · Cited by 65
Eigl, B. J., North, S. A., Winquist, E., Finch, D. L., Wood, L. A., Sridhar, S. S., Powers, J., Good, J. L., Sharma, M., Squire, J. A., et al. (2015) · Investigational New Drugs · doi:10.1007/s10637-015-0252-4 · Cited by 65
Child, F. J., Ortiz-Romero, P. L., Alvarez, R., Bagot, M., Stadler, R., Weichenthal, M., Alves, R., Quaglino, P., Beylot-Barry, M., Cowan, R. A., et al. (2016) · British Journal of Dermatology · doi:10.1111/bjd.14427 · Cited by 65
Cuyàs, E., Gumuzio, J., Verdura, S., Brunet, J., Bosch‐Barrera, J., Martín-Castillo, B., Alarcón, T., Encinar, J. A., Martín, Á. G., & Menéndez, J. A. (2020) · Aging · doi:10.18632/aging.102887 · Cited by 65
Cottone, L., Cribbs, A. P., Khandelwal, G., Wells, G., Ligammari, L., Philpott, M., Tumber, A., Lombard, P., Hookway, E. S., Szommer, T., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-1387 · Cited by 65
Saxena, K., Herbrich, S. M., Pemmaraju, N., Kadia, T. M., Dinardo, C. D., Borthakur, G. M., Pierce, S. A., Jabbour, E. J., Wang, S. A., Bueso-Ramos, C., et al. (2021) · Cancer · doi:10.1002/cncr.33690 · Cited by 65
Rodon, J. A., Rodríguez, E., Maitland, M. L., Tsai, F. Y.-C., Socinski, M. A., Berlin, J. D., Thomas, J. S., Baghdadi, T. A., Wang, I. ‐., Guo, C., et al. (2024) · ESMO Open · doi:10.1016/j.esmoop.2024.102961 · Cited by 65
Guan, Y., Tiwari, A. D., Phillips, J. G., Hasipek, M., Grabowski, D., Pagliuca, S., Gopal, P., Kerr, C. M., Ademà, V., Radivoyevitch, T., et al. (2020) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-20-0173 · Cited by 64
Kalantar‐Zadeh, K., Schwartz, G. G., Nicholls, S. J., Buhr, K. A., Ginsberg, H. N., Johansson, J. O., Kulikowski, E., Lebioda, K. E., Toth, P. P., Wong, N. C. W., et al. (2021) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.16751020 · Cited by 64
The Anticancer Potential of Plant-Derived Nutraceuticals via the Modulation of Gene Expression
Vrânceanu, M., Galimberti, D., Banc, R., Dragoş, O., Cozma-Petruț, A. P., Hegheş, S. C., Voștinaru, O., Cuciureanu, M. D., Stroia, C. M., Miere, D., et al. (2022) · Plants · doi:10.3390/plants11192524 · Cited by 64
The transcriptional regulation role of BRD7 by binding to acetylated histone through bromodomain
Peng, C., Jie, Z., Ying, L. H., Ming, Z., Li, W. L., Hong, Z. Q., Xin, Y. Y., Wei, X., Rong, S. S., Ling, L. X., et al. (2005) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20645 · Cited by 63
Sborov, D. W., Canella, A., Hade, E. M., Mo, X. M., Khountham, S., Wang, J., Ni, W., Poi, M. J., Coss, C. C., Liu, Z., et al. (2017) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2017.1298751 · Cited by 63
Wang, Y., Li, H., Zhang, Y., Jiang, R.-X., Xu, J., Gu, J., Jiang, Z., Jiang, Z., You, Q., & Guo, X. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01374 · Cited by 63
Non-canonical functions of UHRF1 maintain DNA methylation homeostasis in cancer cells
Yamaguchi, K., Chen, X., Rodgers, B., Miura, F., Bashtrykov, P., Bonhomme, F., Salinas‐Luypaert, C., Haxholli, D., Gutekunst, N., Aygenli, B. Ö., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-47314-4 · Cited by 63
Choy, E., Flamand, Y., Balasubramanian, S., Butrynski, J. E., Harmon, D. C., George, S., Cote, G. M., Wagner, A. J., Morgan, J. A., Sirisawad, M., et al. (2015) · Cancer · doi:10.1002/cncr.29175 · Cited by 62
Yuan, Z., Sun, Q., Li, D., Miao, S., Chen, S., Song, L., Gao, C., Chen, Y., Tan, C., & Jiang, Y. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.04.017 · Cited by 62
Self-citationEsteve‐Puig, R., Climent, F., Piñeyro, D., Domingo‐Doménech, E., Dávalos, V., Encuentra, M., Rea, A., Espejo‐Herrera, N., Soler, M., Lopez, M., et al. (2020) · Blood · doi:10.1182/blood.2020005823 · Cited by 62
Kimura, K., Kanto, T., Shimoda, S., Harada, K., Kimura, M., Nishikawa, K., Imamura, J., Ogawa, E., Saio, M., Ikura, Y., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104069 · Cited by 62
From a novel HTS hit to potent, selective, and orally bioavailable KDM5 inhibitors
Liang, J., Labadie, S. S., Zhang, B., Ortwine, D. F., Patel, S. D., Vinogradova, M. V., Kiefer, J. R., Mauer, T., Gehling, V. S., Harmange, J.-C., et al. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.05.016 · Cited by 61
Extended dosing with CC‐486 (oral azacitidine) in patients with myeloid malignancies
Savona, M. R., Kolibaba, K. S., Conkling, P., Kingsley, E. C., Becerra, C. R., Morris, J. C., Rifkin, R. M., Laille, E. J., Kellerman, A. J., Ukrainskyj, S. M., et al. (2018) · American Journal of Hematology · doi:10.1002/ajh.25216 · Cited by 61
Arifuzzaman, S., Khatun, M. R., & Khatun, R. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110392 · Cited by 61
Safety and efficacy of BAY1436032 in IDH1-mutant AML: phase I study results
Heuser, M., Palmisiano, N. D., Mantzaris, I., Mims, A. S., Dinardo, C. D., Silverman, L. R., Wang, E. S., Fiedler, W., Baldus, C. D., Schwind, S., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0996-5 · Cited by 61
Huang, Y. R., Sendzik, M., Zhang, J., Gao, Z., Sun, Y., Wang, L., Gu, J., Zhao, K., Yu, Z., Zhang, L., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c02148 · Cited by 61
Small-Molecule Inhibition of the Acyl-Lysine Reader ENL as a Strategy against Acute Myeloid Leukemia
Liu, Y., Li, Q., Alikarami, F., Barrett, D. R., Mahdavi, L., Li, H., Tang, S., Khan, T. A., Michino, M., Hill, C., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1307 · Cited by 61
Overcoming Clinical Resistance to EZH2 Inhibition Using Rational Epigenetic Combination Therapy
Kazansky, Y., Cameron, D., Mueller, H. S., Demarest, P., Zaffaroni, N., Arrighetti, N., Zuco, V., Kuwahara, Y., Somwar, R., Ladanyi, M., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-0110 · Cited by 61
Ray, K. K., Nicholls, S. J., Ginsberg, H. N., Johansson, J. O., Kalantar‐Zadeh, K., Kulikowski, E., Toth, P. P., Wong, N. C. W., Cummings, J. L., Sweeney, M., et al. (2019) · American Heart Journal · doi:10.1016/j.ahj.2019.08.001 · Cited by 60
Tayari, M. M., Santos, H. G. D., Kwon, D., Bradley, T., Thomassen, A., Chen, C. Y., Dinh, Y. T., Perez, A., Zelent, A., Morey, L., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4054 · Cited by 60
Ding, P., He, A., He, S., Ge, G., Wang, S., Ci, W., Li, X., Xia, D., & Zhou, L. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.67329 · Cited by 60
Hollebecque, A., Salvagni, S., Plummer, R., Niccoli, P., Capdevila, J., Curigliano, G., Moreno, V., de Braud, F., de Villambrosía, S. G., Martín-Romano, P., et al. (2022) · Cancer · doi:10.1002/cncr.34366 · Cited by 60
ENGAGE- 501: phase II study of entinostat (SNDX-275) in relapsed and refractory Hodgkin lymphoma
Batlevi, C. L., Kasamon, Y., Bociek, R. G., Lee, P., Gore, L., Copeland, A., Sorensen, R., Ordentlich, P., Cruickshank, S., Kunkel, L., et al. (2016) · Haematologica · doi:10.3324/haematol.2016.142406 · Cited by 59
Perner, F., Gadrey, J. Y., Xiong, Y., Hatton, C., Eschle, B. K., Weiss, A., Stauffer, F., Gaul, C., Tiedt, R., Perry, J. A., et al. (2020) · Blood · doi:10.1182/blood.2020006113 · Cited by 59
Small molecule inhibitors targeting m6A regulators
Feng, G., Wu, Y., Hu, Y., Wen, S., Yang, X. J., Li, Y., Ouyang, L., & Wang, G. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01546-5 · Cited by 59
Cosío, B. G., Shafiek, H., Iglesias, A., Yáñez, A. M., Córdova, R., Palou, A., Rodriguez‐Roisin, R., Peces‐Barba, G., Pascual-Guàrdia, S., Gea, J., et al. (2016) · CHEST Journal · doi:10.1016/j.chest.2016.04.011 · Cited by 58
Abaza, Y. M., Kadia, T. M., Jabbour, E. J., Konopleva, M. Y., Borthakur, G., Ferrajoli, A., Estrov, Z., Wierda, W. G., Alfonso, A., Chong, T. H., et al. (2017) · Cancer · doi:10.1002/cncr.30949 · Cited by 58
Zhang, M., Fang, Y., Wang, L., Cheng, S., Fu, D., He, Y., Zhao, Y. F., Wang, C.-F., Jiang, X., Song, Q., et al. (2020) · Clinical Epigenetics · doi:10.1186/s13148-020-00948-9 · Cited by 58
Self-citationLv, Y., Li, T., Yang, M., Su, L., Zhu, Z., Zhao, S., Zeng, W., & Zheng, Y. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.684398 · Cited by 58
Self-citationTomassi, S., Romanelli, A., Zwergel, C., Valente, S., & Mai, A. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00226 · Cited by 58
Locked nucleic acid (LNA): A modern approach to cancer diagnosis and treatment
Kamali, M. J., Salehi, M., Fatemi, S., Moradi, F., Khoshghiafeh, A., & Ahmadifard, M. (2022) · Experimental Cell Research · doi:10.1016/j.yexcr.2022.113442 · Cited by 58
Hagemann, S., Misiak, D., Bell, J. L., Fuchs, T., Lederer, M., Bley, N., Hämmerle, M., Ghazy, E., Sippl, W., Schulte, J. H., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01792-0 · Cited by 58
Kong, Y., Yu, J., Ge, S., & Fan, X. (2023) · The Innovation · doi:10.1016/j.xinn.2023.100452 · Cited by 58
Non‐coding RNAs in cancer immunotherapy: Predictive biomarkers and targets
Alahdal, M., & Elkord, E. (2023) · Clinical and Translational Medicine · doi:10.1002/ctm2.1425 · Cited by 58
Methylation-Based Therapies for Colorectal Cancer
Cervena, K., Siskova, A., Buchler, T., Vodicka, P., & Vymetalkova, V. (2020) · Cells · doi:10.3390/cells9061540 · Cited by 57
SGI‐110 and entinostat therapy reduces lung tumor burden and reprograms the epigenome
Tellez, C. S., Grimes, M. J., Picchi, M. A., Liu, Y., March, T. H., Reed, M. D., Oganesian, A., Taverna, P., & Belinsky, S. A. (2014) · International Journal of Cancer · doi:10.1002/ijc.28865 · Cited by 57
Cited by
Age reprogramming: Innovations and ethical considerations for prolonged longevity (Review)
Saliev, T., & Singh, P. (2025) · Biomedical Reports · doi:10.3892/br.2025.1974 · Cited by 14
Metadata
- Authors
- Dai, W., Qiao, X., Fang, Y., Guo, R., Bai, P., Liu, S., Li, T., Jiang, Y., Wei, S., Na, Z., Xiao, X., & Li, D.
- Venue
- Signal Transduction and Targeted Therapy
- Published
- 2024-11-26
- Volume
- 9
- Issue
- 1
- Pages
- 332-332
- ISSN
- 2059-3635 (ISSN-L)
- OpenAlex
- W4404726166
- Cited by
- 339
- References
- 1,077
- FWCI
- 39.39
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.